Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + trastuzumab
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + trastuzumab is an investigational combination therapy consisting of two agents with distinct mechanisms of action. Cabozantinib is a small molecule tyrosine kinase inhibitor that targets multiple kinases involved in tumor growth, angiogenesis, and metastasis, including MET, VEGFR2, AXL, ROS1, TYRO3, MER, KIT, TRKB, FLT3, and TIE2. Trastuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular domain of the HER2 receptor on tumor cells. The combination has been studied primarily in patients with HER2-positive breast cancer brain metastases to evaluate efficacy and tolerability. Cabozantinib inhibits pathways critical for tumor vascularization and invasiveness while trastuzumab blocks HER2-mediated signaling and induces immune-mediated cytotoxicity against HER2-overexpressing cells[1][4][6][8].
- Other names
- cabozantinib and trastuzumabcabozantinib plus trastuzumab
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TEK (Tie2)RET (Rearranged during transfection receptor tyrosine kinase)NTRK2 (Tropomyosin-related kinase receptor type B)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on cabozantinib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + trastuzumab.